ANEB
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q2 | -0.05 | $0 | -$1M |
| 2025 Q1 | -0.05 | $0 | -$1M |
| 2025 Q4 | -0.05 | $0 | -$2M |
| 2025 Q3 | -0.04 | $0 | -$2M |
| 2024 Q2 | -0.09 | $0 | -$1M |
| 2024 Q1 | -0.08 | $0 | -$2M |
| 2024 Q4 | -0.05 | $0 | -$2M |
| 2024 Q3 | -0.06 | $0 | -$1M |